Pomerantz Law Firm Files Class Action Against Sarepta Therapeutics Over Securities Fraud Allegations

Investor Alert: Class Action Against Sarepta Therapeutics

On July 12, 2025, Pomerantz LLP, a law firm renowned for its efforts in corporate and securities class litigation, announced the initiation of a class action lawsuit against Sarepta Therapeutics, Inc. (NASDAQ: SRPT). This legal action pertains to allegations that Sarepta and several of its executives may have engaged in securities fraud or other unlawful business activities. Investors who have suffered losses as a result of their investment in Sarepta are urged to take immediate action.

Key Information for Investors

Investors are advised to contact Danielle Peyton of Pomerantz LLP at [email protected] or call 646-581-9980. Those who want to reach out via email should include relevant details such as their mailing address, phone number, and the number of shares of Sarepta they purchased. Furthermore, investors have until August 25, 2025, to request the court to appoint them as Lead Plaintiff for the class if they acquired Sarepta securities during the specified Class Period.

Background of the Lawsuit

The lawsuit stems from significant adverse events linked to Sarepta's Duchenne muscular dystrophy drug, ELEVIDYS. On March 18, 2025, the company publicly reported the unfortunate death of a young patient suffering from Duchenne muscular dystrophy, shortly after treatment with ELEVIDYS, which resulted in acute liver failure. This tragic news caused Sarepta's stock to plummet by 27.44% in one day, closing at $73.54 per share.

Shortly after, on April 4, 2025, the company announced that authorities from an EU member state had requested the independent data monitoring committee to investigate the death. In tandem with this development, Sarepta decided to suspend recruitment for part of the ELEVIDYS clinical trials. Investors reacted to this news with further selling, leading to a 7.13% decline in share price, which closed at $54.43.

The situation escalated when, on June 15, 2025, Sarepta disclosed a second death caused by acute liver failure related to ELEVIDYS. This prompted the company to halt its ongoing clinical trials and temporarily suspend the distribution of the drug to non-ambulatory patients. Following this announcement, Sarepta's stock fell dramatically by 42.12% to close at $20.94 per share.

Additionally, the U.S. Food and Drug Administration (FDA) released a Safety Communication on June 24, 2025, confirming that it had received reports of two fatalities and was probing the risk of acute liver failure associated with ELEVIDYS. This news further compounded the negative sentiment around Sarepta, resulting in an 8.01% drop in stock price, finishing at $17.46 the next day.

Legal Expertise of Pomerantz LLP

Pomerantz LLP is recognized for its pioneering work in securities class actions, having been founded by Abraham L. Pomerantz, the dean of the class action bar. With over 85 years of experience, Pomerantz remains committed to representing victims of securities fraud and corporate misconduct. The firm has successfully secured multimillion-dollar awards for class members in the past. Investors are encouraged to stay informed and act swiftly regarding this case, as participation in the class action could be vital for recouping losses.

For complete details about the complaint related to Sarepta Therapeutics and to obtain a copy, you can visit Pomerantz's website.

In conclusion, if you believe you have been adversely affected by investment in Sarepta Therapeutics, it is imperative to seek counsel and participate in this class action lawsuit before it's too late.